| 15.69 -0.37 (-2.3%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.22 | 1-year : | 23.62 |
| Resists | First : | 17.31 | Second : | 20.22 |
| Pivot price | 15.19  |
|||
| Supports | First : | 12.39 |
Second : | 9.35 |
| MAs | MA(5) : | 16.12 |
MA(20) : | 14.3 |
| MA(100) : | 10.63 |
MA(250) : | 10.12 |
|
| MACD | MACD : | 1.4  |
Signal : | 1.3 |
| %K %D | K(14,3) : | 73.9 |
D(3) : | 80.8 |
| RSI | RSI(14): 62.5 |
|||
| 52-week | High : | 17.31 | Low : | 5.15 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IMNM ] has closed below upper band by 38.3%. Bollinger Bands are 64.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 20 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 16.39 - 16.48 | 16.48 - 16.54 |
| Low: | 15.29 - 15.38 | 15.38 - 15.44 |
| Close: | 15.57 - 15.7 | 15.7 - 15.81 |
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Fri, 24 Oct 2025
Immunome, Inc. (IMNM) Stock Analysis: A Biotech Contender With A 49% Potential Upside - DirectorsTalk Interviews
Thu, 23 Oct 2025
Immunome’s ADC payload shows promise against cancer resistance By Investing.com - Investing.com South Africa
Thu, 23 Oct 2025
Immunome (IMNM) Unveils Promising Data on Novel ADC Payload HC74 - GuruFocus
Thu, 23 Oct 2025
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance - Business Wire
Fri, 03 Oct 2025
Assessing Immunome (IMNM) Valuation Following New Target Discovery Partnership with Infinimmune - simplywall.st
Thu, 02 Oct 2025
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 7.08e+007 (%) |
| Held by Institutions | 9.9 (%) |
| Shares Short | 13,560 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.8842e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 157.6 % |
| Return on Equity (ttm) | -40.3 % |
| Qtrly Rev. Growth | 1.259e+007 % |
| Gross Profit (p.s.) | 35.79 |
| Sales Per Share | -41.65 |
| EBITDA (p.s.) | -6.1641e+007 |
| Qtrly Earnings Growth | -3.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -179 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.38 |
| Price to Cash Flow | 9.86 |
| Dividend | 0 |
| Forward Dividend | 1.547e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|